A potentially registrational clinical trial to evaluate IMVT-1402 for treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Latest Information Update: 24 Mar 2025
At a glance
- Drugs IMVT-1402 (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
Most Recent Events
- 19 Mar 2025 According to an Immunovant media release, INDs active for both MG and CIDP with pivotal study initiations for lead asset IMVT-1402 in these indications expected imminently.
- 05 Jun 2024 New trial record
- 29 May 2024 According to an Immunovant media release, to optimize the level of disease activity and patient population for an IMVT-1402 clinical trial the company has decided to run the batoclimab CIDP trial approximately two quarters longer prior to unblinding period. Data from batoclimab CIDP trial will be used to optimize design of this trial prior to the end of the fiscal year (by March 31, 2025).